Our treatment strategy focuses on awakening the patient’s immune system by overcoming the suppressive signals released by the tumor.

CD3 Bi-specific Platform

Substitute different Fabs into our CD3 platform to quickly generate bi-specifics that can activate T-cells in an antigen-dependent manner

VEGF Trap Platform

Unique bi-specific VEGF trap design showed significant synergistic anti-tumor effects against a variety of cancers

in vitro System

Development of cell-based assays that can rapidly screen for the biological activity of bi-specific antibodies and identify new surface proteins that can be targeted through immunotherapy

 

News

Featured
Immunowake closes $20M in pre-Series A

Shanghai, China - 15th May 2022. Immunowake has raised $20M in pre-series A financing. This funding round was led by Hyfinity Investments, followed by South China Venture, Lapam Capital, and HEDA Ventures.

Read More →
Immunowake Announces Licensing Agreements with GenSci and GenScript
Immunowake Announces Licensing Agreements with GenSci and GenScript

Birmingham, AL - 5th March 2020. Immunowake Inc. announced that it has entered into agreements with Genescience Pharmaceuticals Co., Ltd and Genscript Biotech Corp (HKG: 1548) in which Immunowake will obtain exclusive licenses to PD-L1 antibodies for the development of multi-target therapeutics. Terms of the agreement were not disclosed.

Read More →
Immunowake raises $3M in Financing
Immunowake raises $3M in Financing

Birmingham, AL - 22nd August 2019. Immunowake has raised $3M in financing, led by Changchun High-tech Industries Group Inc (SZSE: 000661). This investment will be used to accelerate the research, development, and commercialization of Immunowake’s portfolio.

Read More →